News und Analysen
SoftBank’s Chipmaker Deal: A Bottoming for Semiconductor Stocks?
As of March 2025, a new announcement coming from SoftBank revealed a transaction of up to $6.5 billion dollars as the entity decided to purchase a semiconductor manufacturer named Ampere
Santhera informiert am Capital Markets Day über den aktuellen Stand der kommerziellen Einführung von AGAMREE® und zukünftige strategische Prioritäten
Pratteln, Schweiz, 24. März 2025 - Santhera Pharmaceuticals (SIX: SANN) gibt bekannt, dass das Unternehmen an seinem heutigen Capital Markets Day (CMD) in Zürich über die kommerziellen Fortschritte
EQS-News: Formycon lädt zur Telefonkonferenz zu den Ergebnissen des Geschäftsjahres 2024 ein und gibt Teilnahme an internationalen Investorenkonferenzen im 2. Quartal 2025 bekannt
Bayer AG Stock: $2.1 Billion Glyphosate Verdict Intensifies Pressure
A severe setback in ongoing glyphosate litigation has further strained Bayer AG's financial outlook, as a Georgia jury ordered the troubled German pharmaceutical giant to pay approximately $2.1
Bayer AG Stock: $2.1 Billion Roundup Verdict Hits Hard
Bayer AG faces a significant new legal setback as a Georgia jury has ordered the German pharmaceutical and agrochemical giant to pay approximately $2.1 billion (€1.9 billion) in damages over claims
AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
AbbVie Inc. (NYSE: ABBV) is trading near an all-time high after the company announced a licensing agreement with Gubra, a Danish company. The agreement
AbbVie Stock: Legal Battle Weighs on Share Price
AbbVie is experiencing a slight downturn in the stock market, with shares currently trading at $209.96, representing a 0.94 percent decline. The pharmaceutical giant's stock dropped by $2.00
Bristol-Myers Squibb Aktie: Optimismus prägt Strategie
Die Bristol-Myers Squibb Aktie zeigt sich derzeit in solider Verfassung. Der Kurs des Biopharmazie-Riesen kletterte auf 61,04 USD (Stand: 22. März 2025), was einem Anstieg von 1,01% zum Vortag
Johnson & Johnson Stock: $55 Billion U.S. Investment Signals Growth
Johnson & Johnson (J&J) has announced plans to invest more than $55 billion in the United States over the next four years, representing a 25% increase compared to its spending during the previous
EQS-News: Heidelberg Pharma gibt Finanzzahlen bekannt und berichtet über erfolgreichen Geschäftsverlauf 2024
Alnylam Stock: FDA Approves Amvuttra for Rare Heart Disease
Alnylam Pharmaceuticals has secured a significant victory with the FDA's approval to expand Amvuttra's (vutrisiran) use for treating transthyretin amyloidosis cardiomyopathy (ATTR-CM), a rare and
Biomarin Pharmaceutical Stock: Strong Data Boosts Outlook
Biomarin Pharmaceutical recently presented compelling new data for its key medications VOXZOGO and PALYNZIQ at the American College of Medical Genetics and Genomics annual meeting, sparking investor
Evolus Stock: Executives Sell Shares Amid Strong Growth
In March 2025, several top executives at healthcare company Evolus sold significant portions of their company shares through pre-established 10b5-1 trading plans. Director David Moatazedi divested
Johnson & Johnson Stock: Cancer Breakthroughs Amidst Market Challenges
Johnson & Johnson's stock recently experienced a slight setback, declining 1.14 percent to $162.38 amid challenging market conditions. However, the pharmaceutical giant's long-term outlook appears
ANI Stock: Nitazoxanide Tablets Launch Boosts Market Position
ANI Pharmaceuticals, a diversified biopharmaceutical company valued at $1.3 billion, has announced the launch of 500mg Nitazoxanide tablets, a generic version of reference drug Alinia®. This
EQS-News: Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu und genehmigt die Dividende von CHF 1.80 pro Aktie
Pfizer Stock: Company Sells Entire Haleon Stake
Pharmaceutical giant Pfizer has divested its complete shareholding in consumer health company Haleon for approximately £2.5 billion ($3.24 billion). The transaction was executed at 385 pence per
EQS-News: Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation
EQS-News: Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 Finance Contract
Here's Why Ovid Therapeutics Stock Popped Higher Today
Ovid Therapeutics (NASDAQ: OVID) stock rose by more than 18% as of 12 a.m. today. The biopharmaceutical company is devoted to developing medicines for people with epilepsy and other brain
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
On February 17, 2026, 5AM Venture Management reported selling its entire stake in Praxis Precision Medicines (NASDAQ:PRAX), an estimated $9.01 million trade based on last-disclosed position values.
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain
On February 17, 2026, Superstring Capital Management disclosed a new position in Axsome Therapeutics (NASDAQ:AXSM), acquiring 37,433 shares worth $6.84 million in the fourth quarter.
According to a
The Best Healthcare Stocks to Buy With $50 Right Now
It's not hard to find healthcare stocks, including small-cap biotech companies, trading below $50 per share. However, many of these are high-risk investments that are likely to destroy investors'
EQS-News: Newron announces nominations to its Board of Directors at upcoming Annual General Meeting
Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics
Generally, when investors are looking for growth, they turn to industries such as technology. Here, revenue may be rising in the double or even triple digits, leading to explosive stock performance